Dr. Kristi J Keller, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 905 2nd St, Friend, NE 68359 Phone: 402-947-2541 Fax: 402-947-2811 |
News Archive
UAlberta chemistry professor Robert Campbell is developing new ways to see and manipulate the activity of neurons in the brain, which could revolutionize the way we understand the organ that controls most of the activities of the body.
MarketWatch reports that though many tout prevention in relation to heart disease, "chances are your insurance won't cover a trip to a dietician, a gym membership or other services that could help you reduce your risk factors."
Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors with a strong hereditary component. Half the genes whose alterations confer hereditary susceptibility to develop this condition code for enzymes involved in the Krebs cycle, a metabolic route involved in cellular respiration.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.
› Verified 9 days ago